Get the Stockscreener App
17.54
3.30%
0.56
After Hours:
17.50
-0.04
-0.23%
Summit Therapeutics Inc stock is traded at $17.54, with a volume of 4.49M.
It is up +3.30% in the last 24 hours and down -9.49% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$16.98
Open:
$16.98
24h Volume:
4.49M
Relative Volume:
1.37
Market Cap:
$13.61B
Revenue:
$220.00K
Net Income/Loss:
$-1.08B
P/E Ratio:
-12.14
EPS:
-1.4448
Net Cash Flow:
$-326.53M
1W Performance:
-17.50%
1M Performance:
-9.49%
6M Performance:
-2.93%
1Y Performance:
-37.40%
1-Day Range:
$16.55
$17.77
1-Week Range:
$15.14
$22.38
52-Week Range:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.54 | 13.18B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely - Yahoo Finance
Biopharmaceutical News: Summit Therapeutics Stock Plummets After Trial Analysis Misstep - geneonline.com
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies - timothysykes.com
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing - The Globe and Mail
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider LossesHas The Bull Case Changed? - simplywall.st
This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market - Yahoo Finance
TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating - Moomoo
Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results - MarketBeat
SMMT Plunges As Summit Therapeutics Stock Sheds Over 27% - timothysykes.com
Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen - MarketBeat
Summit Therapeutics Inc. Q1 2026 Financial Results: Forward-Looking Statements, Clinical Trial Updates, and Segment Reporting - Minichart
Summit Therapeutics Inc (SMMT) Stock Price, Quote, News & History - Benzinga
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Summit Therapeutics Shock Move Hits Nasdaq Futures - Kalkine Media
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch - Investor's Business Daily
U.S. Markets Closed Mixed Friday As Pershing Square Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics Shares Fall After 1Q Loss Widens - Moomoo
Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge - TechStock²
SMMT Maintains by Piper Sandler -- Price Target Lowered to $16.00 - GuruFocus
Summit Therapeutics (SMMT) Shares Drop 22% After Trial Update - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Summit Therapeutics (SMMT) Sees Significant Drop in Stock Price - GuruFocus
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Summit Therapeutics Stock Dips After Q1 Financial Report - Benzinga
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Summit Therapeutics (SMMT) slides 24.7% as investors digest Q1 loss and an interim trial update that didn’t deliver an early efficacy win - Quiver Quantitative
Summit Therapeutics stock falls after Q1 update (SMMT:NASDAQ) - Seeking Alpha
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - Yahoo Finance
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler - TipRanks
Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - BioSpace
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
Impressive Progress for SMMT with New Bispecific Antibody Develo - GuruFocus
Summit Therapeutics (SMMT) Reports Q1 EPS Beat with Strong Cash Position - GuruFocus
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Summit Therapeutics (SMMT) Attractive After Q1 2026? EPS $(0. - GuruFocus
Press Release: Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - 富途牛牛
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):